Xconomy Forum: What’s Hot in Cancer Immunotherapy

Two or three years ago, people in biotech would have said you were nuts if you had predicted a revival of cancer immunotherapy. Dendreon, the Seattle-based trailblazer, had its well-documented stumbles in the marketplace. But researchers have never been more excited about the various ways of harnessing the immune system to kill cancer cells. Enthusiasm was stirred by a series of groundbreaking presentations at medical meetings in 2013, and one of the richest biotech startup financings in industry history (Seattle-based Juno Therapeutics). Come hear from leading scientists and entrepreneurs from around the country who can candidly discuss the opportunities, and challenges, in this emerging field.

Confirmed Speakers

  • Hans Bishop
    • CEO, Juno Therapeutics
  • Teresa Foy
    • CSO, Oncofactor Corporation
  • Mitch Gold
    • Executive Chairman, Alpine BioSciences
  • Rob Hershberg
    • CEO, VentiRx Pharmaceuticals
  • Deborah Law
    • VP, Biologics Discovery, Merck
  • Ira Mellman
    • VP, Cancer Immunology, Genentech
  • Robert Nelsen
    • Managing Director, Arch Venture Partners
  • Martin Oft
    • VP, Clinical and Regulatory Affairs, ARMO BioSciences
  • Stan Riddell
    • Researcher, Fred Hutchinson Cancer Research Center
  • Chad Robins
    • CEO, Adaptive Biotechnologies

Follow us on Twitter:




Registration: 2:00 – 2:45 pm

Program: 2:45 – 5:45 pm

Networking Reception: 5:45 – 7:00 pm

Full agenda here

Registration Information

Regular Registration: $245

Startup Special: $115

Student: $30

At the Door: $325

Register Now

Fred Hutchinson Cancer Center
Fenwick & West LLP
Wells Fargo Insurance Services